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Defects in Membrane Frizzled-related Protein (MFRP) 
cause autosomal recessive retinitis pigmentosa (RP). MFRP 
codes for a retinal pigment epithelium (RPE)- specific 
membrane receptor of unknown function. In patient-
specific induced pluripotent stem (iPS)-derived RPE cells, 
precise levels of MFRP, and its dicistronic partner CTRP5, 
are critical to the regulation of actin organization. Over-
expression of CTRP5 in naïve human RPE cells pheno-
copied behavior of MFRP-deficient patient RPE (iPS-RPE) 
cells. AAV8 (Y733F) vector expressing human MFRP res-
cued the actin disorganization phenotype and restored 
apical microvilli in patient-specific iPS-RPE cell lines. As a 
result, AAV-treated MFRP mutant iPS-RPE recovered pig-
mentation and transepithelial resistance. The efficacy of 
AAV-mediated gene therapy was also evaluated in Mfr-
prd6/Mfrprd6 mice—an established preclinical model of 
RP—and long-term improvement in visual function was 
observed in AAV-Mfrp-treated mice. This report is the 
first to indicate the successful use of human iPS-RPE cells 
as a recipient for gene therapy. The observed favorable 
response to gene therapy in both patient-specific cell 
lines, and the Mfrprd6/Mfrprd6 preclinical model suggests 
that this form of degeneration caused by MFRP muta-
tions is a potential target for interventional trials.
Received 1 September 2013; accepted 23 May 2014; advance online  
publication 8 July 2014. doi:10.1038/mt.2014.100
INTRODUCTION
Induced pluripotent stem (iPS) cells reprogrammed from somatic 
cells have allowed for the generation of patient-specific disease 
cells in vitro. Interest in generating human-induced pluripotent 
stem (hiPS) cells for stem cell modeling of diseases has overtaken 
that of patient-specific human embryonic stem cells due to the 
ethical, technical, and political concerns associated with the latter. 
As a platform to study patient-specific targeted disease cells, hiPS 
cells have exciting potential in regenerative medicine and human 
disease modeling. The in vitro phenotype of disease-specific iPS-
derived cells can be used to bridge the knowledge gap between the 
clinical phenotype and molecular or cellular mechanisms, along 
with further applications, such as creating new strategies for drug 
screening or developing novel therapeutic agents.1 By using hiPS 
cells, we can prove that a disease is caused by a gene mutation and 
hypothesize potential treatment options before using more expen-
sive animal studies.2 The hiPS cell-based disease models may also 
assist in the development of novel treatments for clinical trials.3–5
Retinitis pigmentosa (RP), which affects approximately 1.5 
million people worldwide, can have autosomal dominant, auto-
somal recessive, or X-linked inheritance patterns. To date, over 60 
genes have been linked to the autosomal and X-linked forms of RP, 
of which over half (35) are associated with the recessive pattern 
of inheritance. One such discovered gene is Mfrp (MIM 606227), 
which encodes a retinal pigment epithelium (RPE)-specific mem-
brane receptor of unknown function.6,7 The MFRP gene encodes a 
type II transmembrane protein similar to WNT-binding frizzled 
proteins. This protein is encoded in a dicistronic transcript, which 
also contains the complete open reading frame (ORF) of the com-
plement C1q tumor necrosis factor-related  protein-5 (C1QTNF5/
CTRP5) (MIM 608752) in the 3’-untranslated region.8,9 MFRP 
and CTRP5 colocalize on within the RPE and ciliary bodies 
and interact directly with each other.7,9–11 MFRP and CTRP5 are 
thought to exist in an antagonistic relationship,7,9,10,12 but there is 
no direct proof published at this time.
Mfrprd6/Mfrprd6 mice have a 4-base pair (bp) deletion in the splice 
donor sequence on intron 4. The subsequent absence of exon 4 causes 
a deletion of 58 amino acids in the MFRP protein.9 These mice have 
autosomal recessive, progressive retinal  degeneration, which is evi-
dent from white spotting visualized during fundus examination. As a 
result, these mice lose photoreceptors with age. Histological analysis 
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shows that the 12–14 cell layers found at birth decline to 4–5 layers 
by 4.5 months, 2–4 layers by 7 months, and 1 layer by 24 months. 
Beginning at 1 month, rod and cone photoreceptor function is pro-
gressively lost, and function is completely absent by 70 weeks.9 As a 
preclinical model of RP, Mfrprd6/Mfrprd6 mice are ideal recipients to 
test in vivo treatment for RP caused by MFRP deficiency.
For human genetic diseases, uncovering the relationship 
between functionally related proteins is a step toward further 
understanding the mechanisms of disease and potential  treatment. 
The goal of this study is to use hiPS cell technology to elucidate 
the role of a novel mutation in the MFRP gene and its putative 
association with RP. Modeling pathogenesis and treatment in vitro 
using patient-specific iPS cells will help to decrease patient risk, 
clarify disease mechanisms, bypass problems related to differences 
among species that arise when using animal models, and reduce 
the cost of clinical trials. In this study, we generated iPS cells from 
two RP patients with MFRP mutations, treated their iPS-RPE cells 
with AAV vector therapy, and used their iPS-RPE cells to identify 
MFRP downstream targets.
RESULTS
Retinitis pigmentosa due to MFRP deficiency
RP in a 19-year-old man (Patient 1, P1) and a 50-year-old woman 
(Patient 2, P2) was diagnosed by the coauthors (SHT, IHM, 
QVH, and LAY). P1 showed a relative preservation of his retina 
compared to other forms of RP (Figure 1a). He did not exhibit 
significant loss of the photoreceptor nuclear layer but had cystic 
degeneration of the macula seen on optical coherence tomograms 
(OCT) (Figure 1e). Full-field electroretinogram (ERG) analysis 
of P1 showed extinguished scotopic rod-specific amplitudes but 
relative sparing of cone responses (Figure 1f). P2 showed macular 
atrophy and extensive subretinal salt-and-pepper RPE mottling 
(Figure 1b). DNA sequencing of MFRP revealed that P1 carried 
a novel homozygous IVS10 +5G>A mutation in the MFRP gene 
(Figure 1c). We confirmed this mutation by DNA sequencing of 
the MFRP gene on parents of P1, and both of the parents were 
heterozygous IVS10 +5G/A (Supplementary Figure S1). P2 car-
ried a homozygous, 1-bp del (492C mutation) in the MFRP gene 
(Figure 1d).
Figure 1  Fundus examination of two MFRP-mutant patients. (a) Color fundus photographs from Patient 1, P1. OD (right eye) (left picture) and 
OS (left eye) (right picture) show relative preservation of the retina compared to other forms of RP. (b) Fundi from Patient 2, P2, OD (left picture) and 
OS (right picture) show typical para-arterial intraretinal migration, macular atrophy, and extensive subretinal salt-and-pepper RPE mottling. (c) Partial 
electropherogram of IVS10 of the MFRP gene with the normal sequence (left) and a G-A +5 mutation (pointed by red arrow) in P1 (right). (d) Partial 
electropherogram of exon 5 in the MFRP gene with the normal sequence (left) and a homozygous 1-bp del (492C) (pointed by red arrow) in P2 (right). 
(e) Optical coherence tomography (OCT) of the macula in P1 shows cystic degeneration and thickening of the foveal region. (f) Full-field electroret-
inogram (ERG) analysis of P1 shows extinguished scotopic rod-specific amplitudes but relative sparing of cone responses.
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Patient-specific cell lines
Fibroblast cells from skin samples of P1 and P2 were transduced 
with lentiviruses carrying the reprogramming genes OCT4, SOX2, 
c-MYC, and KLF4 to establish patient-specific iPS cell lines; fibro-
blasts from a healthy donor’s biopsy sample (female, 56-year-old) 
were also cultured and reprogrammed in the same way to generate a 
wild-type control iPS line. Immunocytochemistry analysis, followed 
by confocal microscopy, demonstrated that all undifferentiated iPS 
lines expressed the pluripotent markers Oct-4, Sox-2, SSEA4, TRA-
1-60, and NANOG (Figure 2a). Teratoma assays confirmed the plu-
ripotency of each iPS line (Supplementary Figure S2).
Following differentiation, pigment clusters derived from iPS 
cells appeared after 6–8 weeks. Under light microscope, the wild-
type control iPS-RPE showed native RPE morphological charac-
teristics, including perinuclear localization of melanin granules. In 
contrast, iPS-RPE cells from both P1 and P2 had abnormal mor-
phology with less pigment, mislocalized pigment distribution, and 
loss of clear cellular boundaries and cell-to-cell contact (Figure 2b). 
Immunoblot analyses for the native, mature RPE-specific mark-
ers RPE65, BESTROPHIN-1, MITF, and VINCULIN confirmed 
the RPE fate of iPS-RPE cells from wild-type control, P1 and P2 
(Figure 2c, quantification shown in Supplementary Figure S3).
AAV2/8(Y733F) gene therapy vectors
The AAV2/8(Y733F)-CMV gene transfer vector13–15 was based 
on pZac2.1. MFRP, CTRP5, or Mfrp cDNA was cloned into this 
expression cassette along with the CMV promoter, a Simian virus 
40 (SV40) site, and a polyA tail flanked by inverted terminal 
repeats (ITRs) (Figure 3). In this report, the AAV2/8(Y733F).
CMV.huMFRP.SV40 vector will be referred to as AAV-MFRP, the 
AAV2/8(Y733F).CMV.huCTRP5.SV40 vector will be referred to 
as AAV-CTRP5, and the AAV2/8(Y733F).CMV.mMfrp.SV40 vec-
tor will be referred to as AAV-Mfrp.
Label-free mass spectrometric proteome profiling
Label-free shotgun proteomic profiling provided data to identify 
key proteins from thousands of proteins and discern differences 
in protein expression phenotypes across cell lines with various 
genotypes.16 β-actin emerged as the most significant differen-
tially-expressed protein in iPS-RPE lines derived from our two 
MFRP-mutant patients; its level was two-fold higher compared to 
wild-type control iPS-RPE. No other protein in the dataset had 
this striking pattern of expression β-actin as a candidate in MFRP 
signaling pathway. Immunoblot analyses confirmed the results 
from the proteomic profiling: similar patterns were observed in 
β-actin expression (Figure 4a), with increased level in iPS-RPE 
derived from our two MFRP-mutant patients compared to wild-
type control iPS-RPE.
MFRP level is inversely proportional to CTRP5 
expression in RPE cells
To explore the relationship between MFRP and CTRP5 in RPE 
cells, antibodies to MFRP and CTRP5 were used to probe extracts 
from iPS-RPE, human autopsy RPE, and AAV-MFRP-transduced 
Figure 2 Establish patient-specific cell lines. (a) Representative immunofluorescence image of pluripotency markers in established patient-specific 
iPS cell line. Scale bar: 100 μm. (b) Light microscopy images of cultured human iPS-RPE cells from a wild-type control donor (left), P1 (middle), and 
P2 (right). For upper panel, scale bar: 50 μm; lower panel, scale bar: 100 μm. (c) Immunoblot analysis of mature RPE specific marker RPE65 (65 kDa), 
BESTROPHIN-1 (68 kDa), MITF (59kDa), and VINCULIN (124 kDa) in iPS-RPE cells from wild-type control donor (WT), P1, and P2. GAPDH serves as 
the loading control.
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HEK293 cells. Immunoblotting results presented that MFRP and 
its dicistronic gene CTRP5 existed in an antagonistic relation-
ship to regulate actin organization. Lack of MFRP expression 
with corresponding increases in CTRP5 and β-actin levels were 
observed in iPS-RPE cells derived from both P1 and P2 compared 
to wild-type control iPS-RPE. When naive human RPE cells, iso-
lated from an autopsied eye, were transduced with AAV-CTRP5, 
a decrease in the MFRP and increase in CTRP5 and β-actin levels 
was observed compared to nontransduced controls. Strong MFRP 
expression and null CTRP5 expression was observed in HEK293 
cells transduced with AAV-MFRP, which served as a positive 
control for AAV-mediated transgene expression, despite loading 
at 20% concentration compared to the RPE experiments. In all 
lanes, CTRP5 expression opposed MFRP expression. Mature RPE 
fates were further confirmed by the expression of RPE-specific 
protein, CRALBP, in all iPS-RPE cells and autopsied RPE, yet not 
in HEK293 cells. The RPE from an autopsied eye with nontreated 
and wild-type control iPS-RPE cells served as the positive control 
(Figure 4a, quantification shown in Supplementary Figures S3 
and S4).
Overexpression of CTRP5 phenocopies the MFRP 
deficiency
In immunoblots, overexpression of CTRP5 led to down-regula-
tion of MFRP in AAV-CTRP5 transduced human autopsy RPE 
cells. To confirm the relationship between MFRP and CTRP5, 
immunofluorescence for rhodamine-phalloidin was performed 
on the wild-type control iPS-RPE, MFRP-deficient iPS-RPE (P1), 
and human autopsy RPE before and after AAV-CTRP5 treatment. 
Under fluorescence microscopy, the wild-type control iPS-RPE 
and nontreated human autopsy RPE showed similar morphology: 
organized actin filaments arranged in dense bands around the cell 
periphery and actin stress fibers extending throughout the cyto-
plasm. Both iPS-RPE cells from P1 and AAV-CTRP5 transduced 
human autopsy RPE showed disorganized and elongated criss-
crossing actin stress fibers, increased numbers of focal adhesions, 
and loss of cell-to-cell contact (Figure 4b).
AAV-MFRP gene therapy rescues dysmorphic MFRP-
deficient iPS-RPE cells
iPS-RPE cells from the two MFRP mutant patients and the 
Mfrprd6/Mfrprd6 mouse were found to be pleiotropic compared to 
the hexagonal RPE cells derived from wild-type control iPS-RPE 
and C57BL/6(B6) mice controls. Flat mount of RPE immunola-
beled for tight-junction zonula occludens (ZO-1) protein from a 
Mfrprd6/Mfrprd6 mouse shows marked variation in cell size com-
pared to the RPE from adult B6 mice, which served as controls 
(Figure 5a). In iPS-RPE, the hexagonal red structure indicates 
the presence of ZO-1 on wild-type control iPS-RPE cells. Cellular 
morphology is lost in iPS-RPE cells from P1 and P2, but the regu-
lar hexagonal pattern of ZO-1 expression was restored in dysmor-
phic iPS-RPE cells from P1 and P2 following AAV-MFRP vector 
treatment (Figure 5b). Microfilament organization of RPE cells 
was assessed by immunofluorescence analysis with rhodamine-
phalloidin staining. Wild-type iPS-RPE shows precisely organized 
β-actin filaments arranged in dense bands around the cell periph-
ery with short actin stress fibers extending throughout the cyto-
plasm. MFRP-deficient iPS-RPE from P1 and P2 exhibit elongated 
crisscrossing actin stress fibers, increased numbers of focal adhe-
sions, and loss of cell-cell contact. AAV-MFRP treatment restored 
actin filament bundle organization to the iPS-RPE from P1 and 
P2. After AAV-MFRP treatment, iPS-RPE cells from P1 and P2 
exhibited hexagonal, organized actin filaments around the cell 
periphery (Figure 5c).
Supernumerary microvilli were observed in Mfrprd6/Mfrprd6 
mice.17 However, human iPS-RPE cells from P1 and P2 showed 
a loss of apical microvilli, which was restored after AAV-MFRP 
treatment (Figure 6). Wild-type iPS-RPE cells were used as a 
control.
In trans-well culture system, wild-type control iPS-RPE cells 
exhibit strong pigmentation whereas the iPS-RPE from P1 and P2 
showed significant loss of pigment. Strikingly, after AAV-MFRP 
transduction, MFRP-mutant iPS-RPE cells regained pigmentation 
(Figure 7a).
Patients with MFRP deficiency lost the RPE barrier function 
and developed cystic degeneration in their maculae (Figure 1e). 
Transepithelial resistance (TER) reveals the status of RPE tight 
junctions. In order to quantify the functional impact of AAV-
MFRP rescue, we used TER to reveal the status of tight junctions 
between iPS-RPE cells treated with and without AAV-MFRP. 
TER in the wild-type control iPS-RPE increased to 320Ω cm−2 
over 5 weeks. The iPS-RPE from both P1 and P2 showed a sig-
nificant improvement (P value = 0.0001183 for P1, and P value 
= 0.000341 for P2) at all weeks tested for cells transduced with 
Figure 3 Schematic representation of the AAV2/8(Y733F)-CMV-vector. A pZac2.1 vector plasmid displaying the complementary DNA (cDNA) 
of human MFRP. (a), human CTRP5 (b), and mouse Mfrp (c) fragments driven by the CMV promoter. The Simian virus 40 (SV40) polyadenylation 
signal is located at the 3′ end of the cDNA. Arrows indicate the direction of transcription, and the 5′- and 3′-inverted terminal repeat (ITRs) of AAV 
are shown.
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the AAV-MFRP vector compared to untreated cells. The TER at 
5 weeks for the AAV-transduced group reached 64 Ω cm−2 for P1 
and 70 Ω cm−2 for P2 (Figure 7b).
AAV-Mfrp provides long-term vision rescue in a 
preclinical model of RP
Quantitative autofluorescence (AF) images in Mfrprd6/Mfrprd6 mice 
showed an increase in punctate and general lipofuscin accumulation 
at 30, 60, and 90 days of age (Figure 8a). To prevent photoreceptor 
cell death in Mfrprd6/Mfrprd6 mice, the right eyes were transduced 
by subretinal injection of the AAV-Mfrp vector on postnatal day 5. 
Compared to the control left eyes of the Mfrprd6/Mfrprd6 mice, AAV-
Mfrp transduction decreased background AF and resulted in fewer 
punctate signals in the treated eye (Figure 8b). Quantification of 
AF showed a significantly decreased AF from a density–volume 
of 137.01 to 43.59 (P value = 0.02) (Figure 8c). Composite dark-
adapted electroretinograms (ERGs), which served as a direct 
proof of retina function, were performed two months after uni-
lateral subretinal injection of wild-type Mfrp via the AAV-Mfrp 
 vector. The other eye served as the untreated control. Rod-specific 
response and maximum response ERGs were recorded for 11 mice. 
The function of both rod and cone photoreceptors increased sig-
nificantly, as evidenced by an increased amplitude of the a-wave 
Figure 4 Immunoblots and immunofluorescence on MFRP-deficient 
and CTRP5-overexpressed RPE cells. (a) Antibodies to MFRP, CTRP5, 
β-actin, CRALBP (RPE-specific marker), and GAPDH were used to 
probe extracts from iPS-RPE from P1, P2 and the wild-type control 
donor (lanes 1-3), autopsy RPE without and with AAV-CTRP5-treated 
(lanes 4-5), and HEK293 cells transduced with AAV-MFRP (lane 6). (b) 
Immunofluorescence for rhodamine-phalloidin on wild-type iPS-RPE 
cells (upper left), MFRP-deficient iPS-RPE cells from P1 (upper right), 
human autopsy RPE (bottom left) and human autopsy RPE treated with 
AAV-CTRP5 vector (bottom right). Scale bar = 10 μm.
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Figure 5 Immunofluorescence on RPE without and with AAV-MFRP 
treated. (a) A flat mount of a RPE sheet immunolabeled for tight-junc-
tion protein ZO-1 from C57BL/6 (B6) mice (left), serve as control and an 
Mfrprd6/Mfrprd6 mouse (right). Scale bar: 100 μm. (b) Immunofluorescence 
staining for ZO-1 (red) and nuclear DAPI staining (blue) on iPS-RPE mono-
layer from wild-type control donor, P1, P2, and iPS-RPE from P1 and P2 
after AAV-MFRP treatment. Scale bar: 50 μm. (c) Rhodamine-phalloidin 
immunofluorescence to assess microfilament organization on iPS-RPE 
cells from control donor, P1, P2, and iPS-RPE from P1 and P2 after AAV-
MFRP treatment. Scale bar: 10 μm.
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(from −42.23 to −143 μv) and b-wave (from 182.7 to 343.8 μv) 
(Figure 8d). Retinal histology of Mfrprd6/Mfrprd6 mutant retina 
and AAV-MFRP-transduced retina presented an increased outer 
nuclear layer (ONL) from a thickness of 4-5 nuclei to a thickness of 
7–8 nuclei (P = 0.0035) (Figure 8e,f). The rescued photoreceptors 
showed improved function and survival for at least 6 months. The 
retina sections of AAV2/8(Y733F)-mMfrp-treated Mfrprd6/Mfrprd6 
mice showed a clear layer of RPE-specific expression, whereas non-
treated Mfrprd6/Mfrprd6 mice did not (Figure 8g). Together, these 
data indicate favorable response to gene therapy in both Mfrprd6/
Mfrprd6 preclinical model and patient-specific cells.
DISCUSSION
Human iPS cell technology provides a platform for investigat-
ing the pathophysiological mechanisms of genetic mutations 
and testing of gene therapy vectors. In this study, we described a 
human iPS cell model of MFRP-deficient RP that possessed func-
tional deficiencies consistent with the clinicopathological features 
of the disease.10,11,15 Focusing on an RPE-based disease model 
presents several advantages. iPS-RPE can be reproducibly iso-
lated and closely monitored both morphologically and function-
ally before experiments, effectively minimizing variability in the 
timing of differentiation. In addition, the RPE, unlike many other 
human cell types, has a well-described culture standard, ensuring 
proper controls.18,19
Our study accomplished four objectives. First, it described 
the successful characterization of human-derived iPS cells from 
two RP patients, one of them with a novel mutation in the MFRP 
gene, homozygous IVS10 +5G>A, which had never been reported 
before. Second, it demonstrated that iPS-derived cells could be 
used as surrogate endpoints for FDA trials and a platform for 
in vitro testing of AAV vectors. Third, this study identified actin 
organization as a downstream target of MFRP and demonstrated 
a new putative function of this novel gene related to cytoskeleton 
organization. Fourth, this study expounded upon the inverse rela-
tionship between MFRP and CTRP5 in human RPE cells.
Traditionally, human genetic diseases were modeled in mice, 
but here, we showed that patient-specific cells and a mouse model 
did not have the same phenotype. Compared to RPE derived from 
wild-type control iPS cells, iPS-RPE from our MFRP patients 
exhibited the loss of apical microvilli as observed by electron 
microscopy (Figure 6). This result was in stark contrast to the phe-
notype of the RPE in Mfrprd6/Mfrprd6 mice, which showed higher 
densities of apical microvilli.17 Because differences in phenotypic 
expression can be observed among species with the same genetic 
Figure 6 Transmission electron microscopy of microvilli in patient-
specific iPS-RPE without and with AAV-MFRP treatment. AAV-MFRP 
treated RPE regain lost microvilli. Scale bar: 1 μm.
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= 0.000341).
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mutation, a study of patient-specific cell lines can be complemen-
tary to mouse models.
The RPE dysmorphology suggested that patient specific RPE 
cells may be more developmentally delayed. Defective MFRP in 
both patients and Mfrprd6/Mfrprd6mice affects proper axial length 
development. To define the biochemical basis of dysmorphic 
RPE, we applied an unbiased proteome screen and identified 
actin via mass spectrometry as a potential protein involved in 
the MFRP pathophysiological pathway (all Excel data provided 
in Supplementary Table S1). To validate the mass spectrometry 
results, we used immunoblots to test the protein with significant 
up or downregulated status. In all MFRP-deficient and CTRP5-
overexpressed RPE lines, β-actin was twofold higher than those 
wild-type controls. To further confirm the immunoblotting 
results, we performed rhodamine-phalloidin and found that 
MFRP-deficient iPS-RPE exhibited increased β-actin expression 
and altered actin polymerization in cellular level compared to 
wild-type control iPS-RPE (Figure 5). These results reinforce our 
novel hypothesis that actin polymerization is a downstream effect 
in the MFRP signaling.
The CTRP5 gene is a dicistronic partner of MFRP, and its 
secreted protein, CTRP5, has been shown to bind to MFRP.20,21 
MFRP and CTRP5 proteins share the functionally related CUB 
and C1q domains. In prokaryotes, polycistronic transcripts com-
monly encode proteins in the same functional pathway, thus con-
stituting an operon. Studies have shown that several dicistronic 
transcripts exist in mammals, and most of these genes encode 
functionally related proteins. As we mentioned, defects in MFRP 
Figure 8 AAV-Mfrp treatment on Mfrprd6/Mfrprd6 mice. (a) Quantitative AF images in Mfrprd6/Mfrprd6 mice at 30, 60, and 90 days of age. (b) Retinal 
fundus AF images of the untreated left eye (left) and the AAV-Mfrp-treated right eye (right) in Mfrprd6/Mfrprd6 mice. A fluorescence standard, shown as a 
bright strip at the top of each image, enabled intensity comparison. (c) Graphical quantification of AF level in treated and nontreated eyes (P = 0.02). 
(d) Rod-specific response and maximum response electroretinograms (ERGs) recordings from 11 Mfrprd6/Mfrprd6 mice that received AAV-Mfrp subreti-
nal injection in right eye at 60 days after the transplantation surgery. Amplitudes of a-wave (**) indicated by letter “a” and b-wave (*) indicated by 
letter “b”. (e) Retinal histology (Hematoxylin and eosin staining) of a representative Mfrprd6/Mfrprd6 mutant retina (right panel) and AAV-MFRP trans-
duced retina (left panel). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. (f) Quantification of ONL of AAV-GFP treated, 
AAV-Mfrp treated and nontreat eyes in Mfrprd6/Mfrprd6 mice. (g) Representative immunofluorescence pictures of retina histology sections stained by 
anti-mouse MFRP from AAV-Mfrp-treated eye (top) and non-treated eye (bottom) of Mfrprd6/Mfrprd6 mice.
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cause autosomal recessive RP. Likewise, the S163R mutation in the 
CTRP5 causes late-onset retinal macular degeneration (LORD), 
an autosomal dominant condition in humans that closely resem-
bles age-related macular degeneration (AMD).22,23 Secretion of 
CTRP5 into the extracellular matrix is impaired by the S163R 
mutation, causing an unfolded protein response within the endo-
plasmic reticulum (ER).20 The heterozygous CTRP5 knock-in 
mouse model (Ctrp5+/S163R), similarly as Mfrprd6/Mfrprd6 mice, also 
develop RPE abnormalities, early dark adaptation abnormali-
ties, accumulation of hyperautofluorescence spots, drusen, Bruch 
membrane abnormalities, and loss of photoreceptors.8,23,24
Like other dicistronic genes, MFRP and CTRP5 may partici-
pate in a common biological pathway in RPE, but no functional 
relationship between MFRP and CTRP5 has been proposed. 
Several studies have confirmed that CTRP5 is a binding partner 
of MFRP,7,9,10,12 but here, we provided evidence for an inverse rela-
tionship between these two binding partners. Expression of MFRP 
in iPS-RPE derived from our two MFRP-mutant patients is lower 
compared to wild-type controls. Additionally, CTRP5 levels are 
higher in MFRP-deficient iPS-RPE cells compared to wild-type 
controls. To validate this finding, we transduced AAV-CTRP5 into 
native RPE cells from an autopsy human eye. After two weeks, 
we measured the expression level of MFRP and CTRP5 in treated 
and nontreated RPE cells. In AAV-CTRP5-transduced RPE cells, 
increased CTRP5 expression led to low MFRP levels. In different 
independent RPE lines, CTRP5 levels are inversely proportional 
MFRP levels.
Besides the expression level, we tested the hypothesis that 
MFRP and CTRP5 play the same functional role in RPE cells. From 
the result of immunoblots, increased β-actin levels were observed 
in both MFRP-deficient RPE cells and CTRP5-overexpressed RPE 
cells. We used rhodamine-phalloidin staining to monitor β-actin 
level in these RPE cell lines and found that overexpression of 
CTRP5 presented similar cellular phenotype as the MFRP defi-
ciency (Figure 4b). We also transduced AAV-CTRP5 into wild-
type control iPS-RPE, and also obtained a similar result (images 
of autopsy RPE and wild-type iPS-RPE transduced by AAV-GFP 
alone as negative control were also included in Supplementary 
Figure S5).
In this report, we presented an expeditious system for the 
study of a new disease allele using iPS cell technology. By creat-
ing a patient-specific model of the disease via iPS, we could study 
the phenotypic properties of the disease and its potential treat-
ments on a virtually unlimited sample of cells. Following our 
in vitro studies, we used a diseased preclinical model to monitor 
physiological responses to the same AAV treatment in vivo. This 
approach using human iPS cells to study genetic diseases allowed 
for the efficient testing of gene therapy in vitro before studying 
live models. In this study, we used patient-specific stem cell lines 
to identify two distinct and novel findings concerning MFRP dis-
ease: (i) MFRP affects downstream actin polymerization, and (ii) 
MFRP coexisted with CTRP5 in an antagonistic, dose-dependent 
relationship. While this approach can be used across specialties, 
it would be particularly important for inherited retinal degenera-
tive diseases, which are often caused by multiple defects and have 
unclear or unknown disease mechanisms. Patient-specific stem 
cells represent an incredible resource for gene therapy studies, not 
only in degenerative disorders of the retina, but also in genetic 
disorders of other organ systems.
MATERIALS AND METHODS
Research subjects. Color fundus pictures, optical coherence tomogra-
phy (OCT), and electroretinogram (ERG) analysis were performed on 
two MFRP-related RP patients in the Department of Ophthalmology, 
Columbia University Medical Center/New York Presbyterian Hospital. 
Skin biopsy samples were obtained (IRB Protocol AAAF1849) from the 
two patients and a healthy subject using local anesthesia (lidocaine) and a 
biopsy-punch (McKesson, VA). The samples were processed and cultured 
as previously described.18,25
The mouse procedures were approved by the Institutional Animal 
Care and Use Committee of Columbia University. Mfrprd6/Mfrprd6 mice 
were used in accordance with the Statement for the Use of Animals in 
Ophthalmic and Vision Research of the Association for Research in 
Vision and Ophthalmology.
MFRP sequencing. Genomic DNA from both patients was isolated from 
peripheral blood lymphocytes according to standard methods. The entire 
coding sequence and exon-intron boundaries of MFRP (13 exons) were 
amplified by PCR using pairs of primers that were designed based on the 
published consensus sequences.12 Direct sequencing of the PCR-amplified 
products was analyzed by the Genwize Company (NJ). All MFRP exon 
data are available at Gene Expression Omnibus (MIM 606227).
Generation and maintenance of hiPS cell lines. Primary fibroblasts from 
two RP patients and one healthy donor were converted into pluripotent 
stem cells using lentiviruses carrying the reprogramming genes OCT4, 
SOX2, c-MYC, and KLF4, following the previously established protocol. All 
hiPS lines were maintained in hiPSC medium as previously described.18,26 
All iPS cells were passaged every 3–4 days.
Differentiation of hiPSC lines. iPS differentiation started at passage 9 for 
all iPS lines in this study. For differentiation, hiPS colonies were cultured 
as floating clusters in 6-well culture dishes (Costar, Corning, Corning, 
NY) pretreated with MEFs in knockout medium (KOM) consisting of 
KO-DMEM, 15% KO serum replacement, 1% nonessential amino acids, 
2 mmol/l glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin (all from 
GIBCO-BRL), and 10 mmol/l nicotinamide (NIC) (Sigma-Aldrich, St 
Louis, MO).27 After 6–10 weeks, pigmented clusters were formatted and 
plated on 1% matrigel-coated dishes in RPE culture medium according to a 
previous protocol28 for a characterization assay. To obtain a monolayer for 
the function assay, after 8 weeks of differentiation, the pigmented areas were 
isolated manually and plated in 12-well transwell plates (Costar, Corning). 
RPE cells derived from iPS cells (iPS-RPE) were maintained in MEM (α 
modification, Sigma-Aldrich, M-4526) -based RPE medium, which con-
tains N1 supplement (5 ml per 500 ml medium), Taurine (125 mg per 500 ml 
medium), Hydrocortisone (10 μg per 500 ml medium), Triiodo-thyronin 
(0.0065 μg per 500 ml medium) (all from Sigma-Aldrich), 2 mmol/l gluta-
mine, 50 U/ml penicillin-streptomycin, 1% nonessential amino acids and 
10% fetal bovine serum (all from GIBCO-BRL), for 6–8 weeks to allow 
them to form a functional monolayer and to reproduce pigment.
Human autopsy RPE isolation. Human autopsy RPE cells were isolated 
and cultured from human eye samples obtained from New York Eye 
Bank as described previously.2 In brief, the eyecup, with anterior portions 
removed, was incubated at 37 °C for 60 minutes. The retina was then sepa-
rated from the optic nerve. Next, RPE-Bruch’s membrane and the com-
bined tissues were separated from the choroid layer and transferred to a 
15 ml conical tube containing 0.05% trypsin-EDTA. The conical tube was 
then incubated in a 37 °C water bath for 10–15 minutes. After centrifu-
gation at 1.4 rpm for 4 minutes, the pellet was then resuspended in RPE 
medium and plated on a petri dish.
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Construction of AAV vectors. AAV serotype 2/8 capsids, which contain a 
point mutation in the surface-exposed tyrosine residue AAV2/8(Y733F), 
were used for packaging the human MFRP, human CTRP5, and mouse 
Mfrp constructs. Vector plasmids were constructed by inserting the CMV 
promoter region and the full-length MFRP, CTRP5, and Mfrp cDNA 
fragments into the pZac2.1 plasmid to generate pZac2.1.CMV.huMFRP.
SV40, pZac2.1.CMV.huCTRP5.SV40, and pZac2.1.CMV.mMfrp.SV40 
plasmids.14 The AAV vectors were created, packaged, and purified at the 
Penn Vector Corporation (University of Pennsylvania, PA). AAV-GFP vec-
tor were obtained from UNC Vector Core Services (University of North 
Carolina at Chapel Hill, NC).
Transduction of AAV vectors in vitro. At passage 2, iPS-RPE cells from 
P1, P2 and wild-type control had been moved in trans-well culture system 
(Costar, 3460). Wild-type control iPS-RPE cells were divided into 4 wells. 
iPS-RPE cells from either P1 or P2 were divided into 8 wells, 4 of which 
received AAV-MFRP treatment and 4 served as untreated controls. Two 
lines of patient-specific iPS-RPE and HEK293 cells also had been grown in 
24-well flat dish for AAV-MFRP infection.
All cells mentioned above were infected with the AAV-MFRP vector 
at a multiplicity of infection (MOI) of 1 × 104 in serum-free RPE medium.29 
After 24 hours, the virus-containing medium was replaced with fresh RPE 
medium with 5% serum to continue normal RPE culture. One week later, 
the steps mentioned above were repeated. Human RPE cells, isolated from 
an autopsied eye shell, were cultured in 6-well plates and infected with 
the AAV-CTRP5 vector at an MOI of 1 × 104 as described above. Wild-
type control iPS-RPE cells and human autopsy RPE cells were cultured on 
cover slip and transduced with the AAV-GFP vector at an MOI of 1 × 104 as 
described above.
Transduction of AAV vectors in vivo.  To test whether AAV2/8(Y733F)-
mMfrp can restore vision in Mfrprd6/Mfrprd6 mice, we injected 
AAV2/8(Y733F)-mMfrp (1.23e12 genome copy/ml) into the subretinal 
space of the right eye of Mfrprd6/Mfrprd6 mice at postnatal day 5. Injection 
of 1 μl of virus particle suspension into the sclera limbus caused an ideal 
bleb detachment at the retinal site of the injection, as evaluated by postsur-
gical fundus examination. The left eyes of all mice were left untouched and 
maintained as a control for experimental analyses. Anesthesia and surgery 
were performed as previously described.30
Proteomic analysis. Shotgun proteomic mass spectrometry-based mea-
surements were performed in triplicate on patient specific iPS-RPE and 
wild-type control iPS-RPE from P1 and P2. A liquid chromatography-mass 
spectrometry (LC-MS) approach was used for the relative quantitation and 
simultaneous identification of proteins from all three samples, including 
triplicate LC/MS/MS chromatograms (technical replicates) collected for 
each of the three biological replicates. We used Synapt G2 quadrupole-time-
of-flight mass spectrometry (Waters Corporation, Milford, MA) to compare 
proteome subtraction of iPS-derived RPE cell lines from two MFRP mutant 
patients and one healthy donor. The data were analyzed with a ProteinLynx 
Global Server and TransOmics software (Waters Corporation).
Cells were lysed in M-PER mammalian protein extraction reagent 
buffer (cat# 78501; Pierce) with proteinase inhibitor (Roche Diagnostics, 
IN). Total protein was quantified using a Bio-Rad protein reader. Protein 
samples (20 μg) were then separated on a 10% Tris–Cl gradient gel and 
electroblotted onto a nitrocellulose membrane. The membranes were 
incubated in blocking buffer for 1 hour at room temperature, washed 
three times in PBS + 0.1% Tween for 5 minutes each, and incubated with 
primary antibody in blocking buffer overnight at 4 °C. Primary antibodies 
against the following proteins were used for western blots: RPE65 (mouse 
monoclonal, 1:2,000, Novus Biologicals, Littleton, CO), BESTROPHIN-1 
(rabbit monoclonal, 1:500, Abcam, Cambridge, MA), MITF (mouse 
monoclonal, 1:500, Abcam), VINCULIN (Rabbit monoclonal, 1:1,000, 
Abcam), MFRP (goat polyclonal, 1:1,000, R&D, Minneapolis, MN), CTRP5 
(goat polyclonal, 1:1,000, R&D), β-actin (mouse monoclonal, 1:2000, 
Abcam), CRALBP (rabbit polyclonal, 1:400, Santa Cruz, Dallas, TX), 
and GAPDH (mouse monoclonal, 1:5,000, Abcam). Mouse, rabbit, and 
goat secondary antibodies were obtained from Santa Cruz and used at a 
concentration of 1:5,000.
Immunofluorescence. Five antibodies against the pluripotency markers 
Oct-4, Sox-2, TRA-1-60, SSEA4, and NANOG (all 1:500, ASK-306, Applied 
StemCell, Menlo Park, CA) were used to characterize the iPS cells repro-
grammed from the fibroblasts obtained from two MFRP-mutant patients 
and the healthy donor as described previously.18 DAPI was used to stain the 
cell nuclei. To study the change in cell shape between normal and MFRP 
mutant iPS-RPE cells, zonula occludens (ZO)-1 (1:500, 40-2200, Invitrogen 
Life Technologies, Grand Island, NY)  staining was performed on RPE 
isolated from B6 and Mfrprd6/Mfrprd6 mice and iPS-RPE derived from two 
MFRP mutant patients before and after AAV2/8-huMFRP treatment. Alexa 
Fluor 488-conjugated goat antirabbit or Alexa Fluor 555-conjugated goat 
antimouse IgG (1:1,000, Invitrogen, Life Technologies) antibodies were 
used as secondary antibodies. Images for staining with all antibodies were 
obtained using the same settings with a fluorescence microscope (Leica DM 
5000 B, Leica Microsystems, Germany).
Phalloidin staining was performed to distinguish the fibers of RPE cells 
in all iPS-RPE lines. The cells were washed two times with PBS and fixed in 
4% paraformaldehyde for 10 minutes at room temperature. After washing 
with PBS two times, the cells were incubated in 0.1% Triton X-100 and PBS 
for 5 minutes. After two subsequent washes with PBS, phalloidin staining 
was performed for 30 minutes at room temperature. The phalloidin staining 
solution was freshly prepared before use according to the manufacturer’s 
instructions (R415, Invitrogen). The stained cells were observed by confocal 
microscopy (Zeiss LSM5 Confocal Microscopy, Germany).
Transmission electron microscopy. To monitor apical microvilli of RPE 
cells, transmission electron microscopy (TEM) was performed on iPS-RPE 
cells from the two MFRP-mutant patients before and after AAV-huMFRP 
treatment. Selected areas were trimmed for ultrathin sectioning and 
stained with uranyl acetate before visualization by EM.31
Measurement of transepithelial resistance. The transepithelial resistance 
(TER) of confluent, pigmented iPS-RPE monolayers cultured on perme-
able transwell filters was measured using an epithelial volt-ohm meter 
(EVOM2) (World Precision Instruments, Sarasota) according to the man-
ufacturer’s instructions.32 For trans-well culture system in this study, there 
are four wells for each line of P1, P1 after AAV-MFRP treated, P2, P2 after 
AAV-MFRP treated and wild-type control. Each well would be measured 
three times at each time point (weekly). The net TER was calculated by 
subtracting the background measurement obtained from cell-free, matri-
gel-coated transwell filters, and then multiplying the difference by the area 
of the transwell filter to obtain values in Ω/cm2. The net TER comparison 
of patient-specific iPS-RPE lines before and after AAV-MFRP treated was 
conducted using ratio paired t-test statistical analyses.
Quantitative fundus autofluorescence imaging. Mice were anesthetized 
with an intraperitoneal injection of ketamine (100 mg/kg) and xylazine 
(10 mg/kg). Pupils were dilated to an ~2.5 mm (range 2.1–2.9) diameter 
by administering 1% tropicamide and 2.5% phenylephrine 15 minutes 
before image acquisition. The fundus was aligned and focused using the 
near infrared reflectance (NIR-R; 820 nm) mode using high sensitivity to 
ensure an evenly illuminated fundus, followed by lowering the sensitiv-
ity to make the retinal details visible. The retina was then preexposed at 
488 nm in AF mode for 20 seconds to bleach the visual pigment. The detec-
tor sensitivity was set at an optimal range that was then used for all AF 
imaging. To determine reproducibility, two images were acquired in each 
of the two separate sessions. During each session, neither the mouse nor 
the camera was moved. Between the two sessions, the image was realigned 
and refocused, and the mouse was repositioned.33
Electroretinogram (ERG). ERGs were conducted on Mfrprd6/Mfrprd6 mice 
as described previously.19 All manipulations were conducted under dim red 
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light, and Espion ERG Diagnosys equipment (Diagnosys LLC, Lowell, MA) 
was used for the recordings. Adult C57BL/6 (B6) mice were tested at the 
beginning of each session as controls to ensure both eyes had the same ampli-
tude. Before each ERG recording, Mfrprd6/Mfrprd6 mice that were subretinally 
injected with AAV2/8(Y733F)-mMfrp were dark-adapted for 12 hours and 
then anesthetized by intraperitoneal injection of 10% ketamine-xylazine-
PBS solution. Topical proparacaine and tropicamide (1%) were used for local 
anesthesia, and phenylephrine (2.5%) was used for pupillary dilation.
Histology and immunofluorescence of the AAV transduced eyes. After 
subretinal injection of AAV2/8-mMfrp, Mfrprd6/Mfrprd6 mice were sacri-
ficed; then, both eyes were enucleated and fixed in 1:2x Karnovsky fixative 
(2% Paraformaldehyde and 1.5% glutaraldehyde) for 24 hours. The eyes 
were embedded in paraffin and sectioned. Retinal sections stained with 
hematoxylin and eosin were visualized by light microscopy (Leica DM 
5000B, Leica Microsystems, Germany). Retinal frozen sections stained 
with MFRP antibody and DAPI as mentioned above and were examined 
by fluorescence microscopy (Leica DM 5000B, Leica Microsystems).
SUPPLEMENTARY MATERIAL
Figure S1. Pedigree of Patient 1.
Figure S2. Phase images and teratoma assay of patient-specific iPS 
cell lines.
Figure S3. Quantification of RPE markers.
Figure S4. Quantification of MFRP, CTRP5 and β-actin Expression in 
MFRP-deficient and CTRP5-overexpressed RPE cells.
Figure S5. Images of immunofluorescence on iPS-RPE.
Table S1. Upregulated proteins in patient-specific iPS-RPE involved 
with actin cytoskeleton.
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